A 23-year-old Louisiana man has become the first person in the Gulf Coast region to be declared functionally cured of sickle cell disease, marking a major milestone in the use of gene-editing technology to treat the inherited blood disorder.
Daniel Cressy, of Metairie, Louisiana, underwent treatment with Casgevy, the world’s first approved CRISPR/Cas9 gene-editing therapy for sickle cell disease. The treatment involved collecting his own blood-forming stem cells, genetically modifying them in a laboratory, administering chemotherapy to prepare his bone marrow, and then reinfusing the edited cells back into his body. After completing the lengthy process and recovering in hospital, doctors determined that he no longer shows signs of sickle cell disease, describing him as functionally cured.
- Advertisement -
Unlike a traditional bone marrow transplant, which requires a compatible donor, Casgevy uses the patient’s own cells. The gene-editing process enables the body to produce higher levels of healthy fetal hemoglobin, preventing red blood cells from assuming the abnormal sickle shape responsible for painful crises and organ damage.
Cressy was diagnosed with sickle cell disease as an infant and endured years of severe pain, frequent hospitalizations, and limitations on his career ambitions. His dream of becoming a commercial pilot had previously been out of reach because of federal aviation regulations governing individuals with the disease. Following the successful treatment, he hopes to continue pursuing that goal. He is also working on a book about his journey and expanding a nonprofit organization that supports underserved aspiring pilots.
Medical experts caution that “functionally cured” does not necessarily mean every trace of the genetic condition has disappeared. Rather, it means the disease is no longer causing the symptoms and complications that once dominated the patient’s life. Continued medical follow-up is still required to monitor long-term outcomes.
The case represents another significant advance in the treatment of sickle cell disease, a hereditary blood disorder that disproportionately affects people of African ancestry and has historically had limited curative options. Researchers hope the success of gene-editing therapies like Casgevy will expand access to life-changing treatment for thousands of patients worldwide.
